BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 36273219)

  • 1. Plasma proteome profiling identifies changes associated to AD but not to FTD.
    Mofrad RB; Del Campo M; Peeters CFW; Meeter LHH; Seelaar H; Koel-Simmelink M; Ramakers IHGB; Middelkoop HAM; De Deyn PP; Claassen JAHR; van Swieten JC; Bridel C; Hoozemans JJM; Scheltens P; van der Flier WM; Pijnenburg YAL; Teunissen CE
    Acta Neuropathol Commun; 2022 Oct; 10(1):148. PubMed ID: 36273219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein L1 is increased in frontotemporal lobar degeneration post-mortem brain but not in ante-mortem cerebrospinal fluid.
    Hok-A-Hin YS; Dijkstra AA; Rábano A; Hoozemans JJ; Castillo L; Seelaar H; van Swieten JC; Pijnenburg YAL; Teunissen CE; Del Campo M
    Neurobiol Dis; 2022 Oct; 172():105813. PubMed ID: 35820647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration.
    Cervantes González A; Irwin DJ; Alcolea D; McMillan CT; Chen-Plotkin A; Wolk D; Sirisi S; Dols-Icardo O; Querol-Vilaseca M; Illán-Gala I; Santos-Santos MA; Fortea J; Lee EB; Trojanowski JQ; Grossman M; Lleó A; Belbin O
    Mol Neurodegener; 2022 Apr; 17(1):29. PubMed ID: 35395770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain DNA methylomic analysis of frontotemporal lobar degeneration reveals OTUD4 in shared dysregulated signatures across pathological subtypes.
    Fodder K; Murthy M; Rizzu P; Toomey CE; Hasan R; Humphrey J; Raj T; Lunnon K; Mill J; Heutink P; Lashley T; Bettencourt C
    Acta Neuropathol; 2023 Jul; 146(1):77-95. PubMed ID: 37149835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes.
    Lleó A; Irwin DJ; Illán-Gala I; McMillan CT; Wolk DA; Lee EB; Van Deerlin VM; Shaw LM; Trojanowski JQ; Grossman M
    JAMA Neurol; 2018 Jun; 75(6):738-745. PubMed ID: 29554190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers.
    Cousins KAQ; Shaw LM; Chen-Plotkin A; Wolk DA; Van Deerlin VM; Lee EB; McMillan CT; Grossman M; Irwin DJ
    JAMA Neurol; 2022 Nov; 79(11):1155-1164. PubMed ID: 36215050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
    Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
    J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clusters of co-abundant proteins in the brain cortex associated with fronto-temporal lobar degeneration.
    Bridel C; van Gils JHM; Miedema SSM; Hoozemans JJM; Pijnenburg YAL; Smit AB; Rozemuller AJM; Abeln S; Teunissen CE
    Alzheimers Res Ther; 2023 Mar; 15(1):59. PubMed ID: 36949537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with sporadic FTLD exhibit similar increases in lysosomal proteins and storage material as patients with FTD due to GRN mutations.
    Davis SE; Cook AK; Hall JA; Voskobiynyk Y; Carullo NV; Boyle NR; Hakim AR; Anderson KM; Hobdy KP; Pugh DA; Murchison CF; McMeekin LJ; Simmons M; Margolies KA; Cowell RM; Nana AL; Spina S; Grinberg LT; Miller BL; Seeley WW; Arrant AE
    Acta Neuropathol Commun; 2023 Apr; 11(1):70. PubMed ID: 37118844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer's Disease and Frontotemporal Dementia.
    Álvarez-Sánchez L; Peña-Bautista C; Ferré-González L; Balaguer A; Baquero M; Casanova-Estruch B; Cháfer-Pericás C
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YKL-40 changes are not detected in post-mortem brain of patients with Alzheimer's disease and frontotemporal lobar degeneration.
    Hok-A-Hin YS; Hoozemans JJM; Hu WT; Wouters D; Howell JC; Rábano A; van der Flier WM; Pijnenburg YAL; Teunissen CE; Del Campo M
    Alzheimers Res Ther; 2022 Jul; 14(1):100. PubMed ID: 35879733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype.
    Woollacott IOC; Nicholas JM; Heller C; Foiani MS; Moore KM; Russell LL; Paterson RW; Keshavan A; Schott JM; Warren JD; Heslegrave A; Zetterberg H; Rohrer JD
    Dement Geriatr Cogn Disord; 2020; 49(1):56-76. PubMed ID: 32344399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features of the behavioural variant of frontotemporal dementia that are useful for predicting underlying pathological subtypes of frontotemporal lobar degeneration.
    Kobayashi Z; Arai T; Kawakami I; Yokota O; Hosokawa M; Oshima K; Niizato K; Shiraishi A; Akiyama H; Mizusawa H
    Psychogeriatrics; 2018 Jul; 18(4):307-312. PubMed ID: 30133939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest.
    Foiani MS; Cicognola C; Ermann N; Woollacott IOC; Heller C; Heslegrave AJ; Keshavan A; Paterson RW; Ye K; Kornhuber J; Fox NC; Schott JM; Warren JD; Lewczuk P; Zetterberg H; Blennow K; Höglund K; Rohrer JD
    J Neurol Neurosurg Psychiatry; 2019 Jul; 90(7):740-746. PubMed ID: 30981993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study.
    Kuiperij HB; Versleijen AA; Beenes M; Verwey NA; Benussi L; Paterlini A; Binetti G; Teunissen CE; Raaphorst J; Schelhaas HJ; Küsters B; Pijnenburg YA; Ghidoni R; Verbeek MM
    J Alzheimers Dis; 2017; 55(2):585-595. PubMed ID: 27662293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct molecular patterns of TDP-43 pathology in Alzheimer's disease: relationship with clinical phenotypes.
    Tomé SO; Vandenberghe R; Ospitalieri S; Van Schoor E; Tousseyn T; Otto M; von Arnim CAF; Thal DR
    Acta Neuropathol Commun; 2020 Apr; 8(1):61. PubMed ID: 32349792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration.
    McMillan CT; Irwin DJ; Avants BB; Powers J; Cook PA; Toledo JB; McCarty Wood E; Van Deerlin VM; Lee VM; Trojanowski JQ; Grossman M
    J Neurol Neurosurg Psychiatry; 2013 Sep; 84(9):949-55. PubMed ID: 23475817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management.
    Seltman RE; Matthews BR
    CNS Drugs; 2012 Oct; 26(10):841-70. PubMed ID: 22950490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Truncated TDP-43 proteoforms diagnostic of frontotemporal dementia with TDP-43 pathology.
    Forgrave LM; Moon KM; Hamden JE; Li Y; Lu P; Foster LJ; Mackenzie IRA; DeMarco ML
    Alzheimers Dement; 2024 Jan; 20(1):103-111. PubMed ID: 37461300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated YKL-40 and low sAPPβ:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD.
    Alcolea D; Irwin DJ; Illán-Gala I; Muñoz L; Clarimón J; McMillan CT; Fortea J; Blesa R; Lee EB; Trojanowski JQ; Grossman M; Lleó A
    J Neurol Neurosurg Psychiatry; 2019 Feb; 90(2):180-186. PubMed ID: 30297518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.